Library Open Repository
lumiracoxib.pdf | Download (98kB)
Available under University of Tasmania Standard License.
Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.
|Journal or Publication Title:||IDrugs|
|Page Range:||pp. 1168-1172|
|Date Deposited:||14 Mar 2008 00:23|
|Last Modified:||18 Nov 2014 03:31|
|Item Statistics:||View statistics for this item|
Actions (login required)
|Item Control Page|